Orion, a Finnish pharmaceutical company and diagnostics company, is to pay Abbott $18 million to re-acquire the rights to the intravenous formulation of its heart failure treatment levosimendan, which is marketed as Simdax.
Following the deal, Orion will have the rights to Simdax in all regions outside of Latin America, where Abbott will...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?